Objective To explore the dignostic value of the candidate molecular markers in Urothelium carcinoma based on Illumina Transcriptome Sequencing. Methods Candidate genes which were screened with transcriptome sequencing were validated by using real-time fluorescent quantitative PCR in 31 pairs of tumor and normal tissues of Urothelium carcinoma patients from Affliated Hai kou Hospital Xiangya School of Medicine Central South University. Results The four candidate genes (CDH1,VEGFA,PTPRF and CLDN7) in tumor tissues were up-regulated compared with normal groups in samples of sequencing. The relative expression of VEGFA mRNA were higher than that in normal tissues. There were significant difference in two groups (P<0.05). PTPRF and CLDN7 were also up-regulated, but no significant difference was found (P > 0.05). PTPRF was closely related with the recurrence of tumor (P=0.002), and the predict sensitivity and speciality rate were 90.0%and 83.3%respectively. Conclusions CDH1 and VEGFA play important roles in the occurrence and development of bladder urothelial carcinoma, and they may be the possible biomarkers. PTPRF is expected to be a molecular reference recurrent predictor of bladder tumor.

Objective To explore the pathogenic mechanism by detecting the expression of membrane glycoprotein in the platelets of nonmuscle myosin heavy chain 9 related disease (MYH9-RD)patients.Methods Periperal bloods were obtained from 11 MYH9-RD patients and 7 normal family members.Flow cytometry was used for detecting the expression of the platelet membrane glycoprotein including GP Ⅱ b/Ⅲa(CD41/61),GP Ⅰ a(CD49b),GP Ⅰ b/Ⅸ/Ⅴ (CD42a) GP Ⅰ b(CD42b) and GPⅣCD36).Results The expression fluorescence intensity of platelet membrane glycoprotein GP Ⅱ b/Ⅲ a CD41/61),GPⅠa(CD49b),GP Ⅰ b/Ⅸ/Ⅴ (CD42a) GP Ⅰ b(CD42b) and GPⅣ (CD36) are 653.7 ±192.7,420.0 ± 151.3,667.7 ± 371.3 and 236.4 ± 64.2 respectively,which are significantly higher than those in normal controls (406.7 ± 126.1,181.2 ± 29.3,271.4 ± 91.6 and 136.1 ± 23.5 ; P ＜ 0.01) ; The expression of GP Ⅰ a(CD49b) was lower in patients with MYH9-RD (139.1 ± 54.9) than that in normal controls (192.2 ± 143.4),but there was no significant difference (P ＞ 0.05).Conclusion In our study,the diverse clinical manifestations in patients with MYH9-RD is probably associated with the expression level of platelet membrane glycoprotein

Objective To establish an ELISA detection method for human serum carbonic anhydrase(CA)Ⅱ antibody,and to evaluate the level of serum CA Ⅱ antibody in patients with hypertensive nephropathy, chronic glomerulonephritis,type 2 diabetic nephropathy and healthy people.Methods To establish the ELISA method using CA Ⅱ,anti-CA Ⅱ monoclonal antibody and enzyme labeled secondary antibody,the evaluation of the degree of precision and sensitivity,and stability and anti-interference performance of the ELISA were made.Results The detection accuracy of serum CA Ⅱ antibody ELISA was 6.0%,the precision between the batches was 8.6%,the sensitivity was 0.032,and with favorable anti-interference performance and stability. The level of serum anti-CA Ⅱ antibody was significantly higher in patients with chronic glomerulonephritis and 2-type diabetic nephropathy compared with the normal control(P<0.05).There was no significant differ-ence in serum CAⅡ antibody level between hypertensive nephropathy group and healthy control group(P>0.05).Conclusion It is feasible to establish a serum CAⅡ antibody ELISA method to meet the needs of clini-cal test.CAⅡ antibody may be used as autoantibody to participate in the development of chronic glomerulone-phritis and type 2 diabetic nephropathy.